Richard K. Burt
Richard K. Burt holds an M.D. degree. He is the Chief of the Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine. Dr. Burt pioneered the use of hematopoietic stem cells to treat autoimmune diseases. He performed and continues to do stem cell transplants in numerous animal autoimmune diseases for preclinical data to support human clinical trials. Dr. Burt performed either America's first or the world's first autologous (one's own) hematopoietic stem cell transplants for numerous immune mediated diseases. Burt is the leader of randomized controlled trials currently ongoing in America for Crohn's disease, multiple sclerosis, and systemic scleroderma. These trials are American Scleroderma Stem cell versus Immune Suppression Trial (ASSIST), Crohns Immune Suppression versus Stem cell Transplant (KISS), and Multiple sclerosis Immune suppression versus Stem cell Transplant (MIST). Dr. Burt has also performed the World's first allogeneic (another person's) stem cell transplant for rheumatoid arthritis and has FDA-approved allogeneic (sibling or cord blood) stem cell transplant trials ongoing for systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and crohn's disease. Current clinical trials being developed by Dr. Burt based on animal stem cell transplant models in Dr. Burt's laboratory include allogeneic stem cell transplants for amyotrophic lateral scerosis (ALS) and primary biliary cirrhosis (PBC). Again based on animal results, Dr. Burt is also using stem cells to treat patients with peripheral vascular disease (PVD) on FDA approved clinical trials and is developing a stem cell transplants protocol for chronic congestive heart failure. His division works closely with world recognized physician investigators from numerous departments and divisions at Northwestern University Feinberg School of Medicine in development of these studies and managing the care of these patients.
Biography Updated on 27 December 2009